Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

Author:

Campa Daniele1,Martino Alessandro2,Macauda Angelica12ORCID,Dudziński Marek3,Suska Anna4,Druzd-Sitek Agnieszka5,Raab Marc-Steffen67,Moreno Victor8ORCID,Huhn Stefanie9,Butrym Aleksandra10,Sainz Juan111213,Szombath Gergely14,Rymko Marcin15,Marques Herlander16,Lesueur Fabienne17181920,Vangsted Annette Juul21,Vogel Ulla22,Kruszewski Marcin23,Subocz Edyta24,Buda Gabriele25,Iskierka-Jażdżewska Elżbieta26,Ríos Rafael111213,Merz Maximilian6,Schöttker Ben2728,Mazur Grzegorz10,Perrial Emeline29,Martinez-Lopez Joaquin30ORCID,Butterbach Katja28,García Sanz Ramón31,Goldschmidt Hartmut632,Brenner Hermann27283334,Jamroziak Krzysztof35,Reis Rui Manuel163637,Kadar Katalin14,Dumontet Charles29,Wątek Marzena38,Haastrup Eva Kannik39,Helbig Grzegorz40,Jurczyszyn Artur4,Jerez Andrés41,Varkonyi Judit14,Barington Torben42ORCID,Grzasko Norbert4344,Zaucha Jan Maciej45,Andersen Vibeke4647,Zawirska Daria48,Canzian Federico2ORCID

Affiliation:

1. Department of Biology, University of Pisa, Pisa, Italy;

2. Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany;

3. Hematology Department, Teaching Hospital No 1, Rzeszów, Poland;

4. Department of Hematology, Jagiellonian University Medical College, Cracow, Poland;

5. Lymphoma Department, Centre of Oncology-Institute of Maria Skłodowska-Curie, Warsaw, Poland;

6. Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany;

7. Max-Eder Research Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ), Heidelberg, Germany;

8. Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), IDIBELL, CIBERESP and Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain;

9. Molecular Biology Laboratory, Section of Multiple Myeloma, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany;

10. Department of Internal and Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland;

11. PTS Granada, Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, Granada, Spain;

12. Monoclonal Gammopathies Unit, University Hospital Virgen de las Nieves, Granada, Spain;

13. Pharmacogenetics Unit. Instituto de Investigación Biosanitaria de Granada (Ibs. Granada), Hospitales Universitarios de Granada / Universidad de Granada, Granada, Spain;

14. Department of Intrenal Medicine, Semmelweis University, Budapest, Hungary;

15. Department of Haematology, Copernicus Town Hospital of Torun, Torun, Poland;

16. Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal;

17. INSERM U900, Paris, France;

18. Institut Curie, Paris, France;

19. Mines ParisTech, Fontainebleau, France;

20. PSL University, Paris, France;

21. Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Denmark;

22. National Research Centre for the Working Environment, Denmark;

23. Department of Hematology, University Hospital, Bydgoszcz, Poland;

24. Department of Haematology, Military Institute of Medicine, Warsaw, Poland;

25. Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy;

26. Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland;

27. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany;

28. Network Aging Research (NAR), University of Heidelberg, Heidelberg, Germany;

29. Cancer Research Center of Lyon, INSERM 1052/CNRS 5286, University of Lyon, Lyon, France;

30. Hospital 12 de Octubre, Complutense University, CNIO, CIBERONC, Madrid, Spain;

31. Department of Hematology, University Hospital of Salamanca, Salamanca, Spain;

32. National Center for Tumor Diseases (NCT), Heidelberg, Germany;

33. Division of Preventive Oncology, National Center for Tumor Diseases (NCT) German Cancer Research Center (DKFZ), Heidelberg, Germany;

34. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany;

35. Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;

36. ICVS/3B’s – PT Government Associate Laboratory, Braga/Guimarães, Portugal;

37. Barretos Cancer Hospital, Molecular Oncology Research Center, S. Paulo, Brazil;

38. Department of Hematology, Holy Cross Oncology Center, Kielce, Poland;

39. Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;

40. Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland;

41. Department of Hematology, University Hospital Morales Meseguer, IMIB, Murcia, Spain;

42. Department of Clinical Immunology, Odense University Hospital, Odense, Denmark;

43. Department of Hematology, St. John’s Cancer Center, Lublin, Poland;

44. Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland;

45. Department of Hematology, Sea Hospital, Gdynia, Poland;

46. IRS-Center Sønderjylland, Aabenraa, Denmark;

47. Institute of Molecular Biology, University of Southern Denmark, Odense, Denmark;

48. Department of Haematology, University Hospital of Cracow, Cracow, Poland

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3